Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NODAGA-SNA006 PET Imaging in Solid Tumors
NCT05126927Phase 1Completed
- Sponsor
- SmartNuclide
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Nanobodies (VHH), Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NODAGA-SNA006, sponsored by SmartNuclide. Primary endpoint: Safety evaluation indicators (Adverse Events) at 12 months. Started Nov 2021; status: completed.
02
Drugs
68Ga-NODAGA-SNA006
Beyond the preview
Go deeper on NCT05126927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126927.